Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal

Myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and related disorders are a heterogeneous class of blood cancers leading to ineffective hematopoiesis in the bone marrow (BM) [1,2]. Approximately 30% of MDS patients progress to acute leukemia. Median survival ranges from 97 months for low-risk categories down to 11 months for high-risk MDS [2]. The incidence of MDS in the general population is approximately four to five per 100,000 people, but this increases with age [1].

Source: Experimental Hematology - November 6, 2018 Category: Hematology Authors: Jane Jialu Xu, Monique F. Smeets, Shuh Ying Tan, Meaghan Wall, Louise E. Purton, Carl R. Walkley Source Type: research